Healthcare
Live Price
Offline$5.50
+0.00% today
1Y Change
-47.12%
Window
Jun 23, 2025 → Jun 1, 2026
Coverage: 240 bars · Jun 23, 2025 → Jun 1, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Redcare Pharmacy N.V. (SAEYY) is a Healthcare stock with a market cap of $990.00M and listed on OTC. The stock last traded around $5.50 and down 47.1% across the available one-year price window (Jun 23, 2025 → Jun 1, 2026). Baseline metrics include revenue growth of +19.2%, EPS growth of +21.1%, a dividend yield of 0.0%. What stands out right now is revenue +19.2%, EPS +21.1%, free cash flow -504.1% with operating margin -1.0% and ROIC -2.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SAEYY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SAEYY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SAEYY Max Drawdown
-68.25%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SAEYY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.1B
-12.0% YoY
FY Net Income
-$74.2M
+4.5% YoY
Free Cash Flow
-$31.5M
+61.9% YoY
Revenue Growth
+19.2%
EPS Growth
+21.1%
Gross Margin
21.7%
Net Margin
-1.3%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.8B | 2.4B | 1.8B | 1.2B | 1.1B |
| Gross Profit | 570M | 546M | 440M | 332M | 267M |
| Operating Income | -23M | -39M | -17M | -69M | -66M |
| EBITDA | 44M | -13M | 51M | -31M | -37M |
| Net Income | -36M | -45M | -12M | -78M | -74M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 92M | 97M | 84M | 66M | 247M |
| Total Assets | 1.2B | 1.0B | 1.0B | 729M | 783M |
| Total Liabilities | 767M | 493M | 470M | 375M | 368M |
| Shareholder Equity | 459M | 484M | 522M | 355M | 415M |
| Total Debt | 415M | 247M | 245M | 255M | 236M |
| Net Debt | 323M | 150M | 161M | 189M | -11M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
12M
+140.0% YoY
Capital Expenditures
43M
+19.4% YoY
Free Cash Flow
32M
+61.9% YoY
Key ratios
Gross Margin
21.7%
Operating Margin
-1.0%
Net Margin
-1.3%
ROE
-7.8%
Debt / Equity
0.91x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.